Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 3, 2008, Pages 311-317

  Deligezer, Ugur ^a,b   Eralp, Yesim ^a   Akisik, Ebru E ^a   Akisik, Elif Z ^a   Saip, Pinar ^a   Topuz, Erkan ^a   Dalay, Nejat ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Oncology Institute   (Turkey)

Author keywords

Adjuvant therapy; Breast cancer; Cell free DNA; Serum; Size distribution

Indexed keywords

CYCLOPHOSPHAMIDE; DNA; DNA FRAGMENT; DOXORUBICIN; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ALU SEQUENCE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER PATIENT; CELL FREE SYSTEM; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DNA; DNA FRAGMENTATION; FEMALE; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD;

EID: 39849106364     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.080     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56: 106-30.
2. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. Br Med J 2000;321:624-8.
3. Saez RA, McGuire WL, Clark GM. Prognostic factors in breast cancer. Semin Surg Oncol 1989;5:102-10.
4. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000;60:892-5.
5. Taback B, Hoon DS. Circulating nucleic acids and proteomics of plasma/serum: clinical utility. Ann NY Acad Sci 2004;1022:1-8.
6. Taback B, Hoon DS. Circulating nucleic acids in plasma and serum: past, present and future. Curr Opin Mol Ther 2004;6:273-8.
7. Gal S, Fidler C, Lo YM, Taylor M, Han C, Moore J, et al. Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR. Br J Cancer 2004;90: 1211-5.
8. Silva JM, Silva J, Sanchez A, Garcia JM, Dominguez G, Provencio M, et al. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin Cancer Res 2002;8:3761-6.
9. Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999;18:65-73.
10. Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 2004;10:6189-93.
11. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 2003;63:7641-5.
12. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005;4:139-63.
13. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61:1659-65.
14. Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res 2003;63:3966-8.
15. Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, Bilchik AJ, et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem 2006;52:1062-9.
16. Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 2006;24:4270-6.
17. Jiang WW, Zahurak M, Goldenberg D, Milman Y, Park HL, Westra WH, et al. Increased plasma DNA integrity index in head and neck cancer patients. Int J Cancer 2006;119:2673-6.
18. Boddy JL, Gal S, Malone PR, Shaida N, Wainscoat JS, Harris AL. The role of cell-free DNA size distribution in the management of prostate cancer. Oncol Res 2006; 16:35-41.
19. Deligezer U, Esin Akisik E, Dalay N. A novel application of melting curves: utility of peak area calculation for relative methylation quantification. Clin Chem Lab Med 2007;45:867-73.
20. Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids - a promising, non-invasive tool for early detection of several human diseases. FEBS Lett 2007;581:795-9.
21. Kamat AA, Sood AK, Dang D, Gershenson DM, Simpson JL, Bischoff FZ. Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR. Ann NY Acad Sci 2006;1075:230-4.
22. Chun FK, Muller I, Lange I, Friedrich MG, Friedrich MG, Erbersdobler A, et al. Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int 2006;98:544-8.
23. Tsang JC, Lo YM. Circulating nucleic acids in plasma/serum. Pathology 2007;39:197-207.
24. Boddy JL, Gal S, Malone PR, Harris AL, Wainscoat JS. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin Cancer Res 2005;11:1394-9.
25. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer - a survey. Biochim Biophys Acta 2007;1775:181-232.
26. Ikpatt O, Ndoma-Egba R, Collan Y. Prognostic value of necrosis in Nigerian breast cancer. Adv Clin Path 2002; 6:31-7.
27. Ikpatt F, Kuopio T, Erekul A, Collan Y. Apoptosis in breast cancer: Nigerian vs. Finnish material. Anal Quant Cytol Histol 2002;24:73-80.
28. Kymionis GD, Dimitrakakis CE, Konstadoulakis MM, Arzimanoglou I, Leandros E, Chalkiadakis G, et al. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in nodenegative breast cancer patients? J Surg Res 2001;99: 161-8.
29. Li S, Zhou Y, Wang R, Zhang H, Dong Y, Ip C. Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates. Mol Cancer Ther 2007; 6:1031-8.
30. Komdeur R, Meijer C, Van Zweeden M, De Jong S, Wesseling J, Hoekstra HJ, et al. Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells. Int J Oncol 2004;25:677-84.
31. Zoli W, Ulivi P, Tesei A, Fabbri F, Rosetti M, Maltoni R, et al. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. Breast Cancer Res 2005;7:R681-9.
32. Kugawa F, Ueno A, Kawasaki M, Aoki M. Evaluation of cell death caused by CDF (cyclophosphamide, doxorubicin, 5-fluorouracil) multi-drug administration in the human breast cancer cell line MCF-7. Biol Pharm Bull 2004;27:392-8.
33. Zehentner BK, Secrist H, Hayes DC, Zhang X, Ostenson RC, Loop S, et al. Detection of circulating tumor cells in peripheral blood of breast cancer patients during or after therapy using a multigene real-time RT-PCR assay. Mol Diagn Ther 2006;10:41-7.
34. Chen Z, Fadiel A, Naftolin F, Eichenbaum KD, Xia Y. Circulation DNA: biological implications for cancer metastasis and immunology. Med Hypotheses 2005;65:956-61.
35. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-50.
36. Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 2005;65:1141-5.